There was a case report using Denosumab as RANKL inhibitor and tyrosine kinase inhibitor Sorafenib to treat a case of chemo-refractory osteosarcoma with an overexpression of RANK and RANKL, showing they were able to achieve a complete metabolic remission (Cathomas et al., 2015). Here, TNFRSF11A is linked to osteosarcoma.